Etoposide, doxorubicin (Adriamycin) and cisplatin regimen in advanced gastric adenocarcinoma: experience with a lower dose schedule

Calogero Cipolla, Carmelo Sciume', Mario Latteri, Vittorio Gebbia, Nicola Gebbia, Nicola Borsellino, Vittorio Gebbia, Pietro Leo, Antonio Longo, Antonio Longo, Pietro Leo, Matteo Florena, Roberto Valenza, Carmelo Sciume, Calogero Cipolla, Mario Latteri, Antonio Testa, Matteo Florena, Pietro Leo

Risultato della ricerca: Articlepeer review

4 Citazioni (Scopus)

Abstract

A phase II trial of etoposide (100 mg/m2) on days 4, 5, 6, doxorubicin (Adriamycin, 20 mg/m2) on days 1, 7, and cisplatin (30 mg/m2) on days 2, 8 (EAP) was carried out in order to reduce toxicity associated with a full-dose EAP regimen for advanced and/or metastatic gastric adenocarcinoma. Out of 21 evaluable patients, 2 (10%) had a complete response (CR), 7 (33%) had a partial response (PR), 4 (20%) showed no change and 8 progressed (38%). The mean duration of response (CR+PR) was 8.4+ months. Survival of the whole group was 7.5+ months. Treatment was quite well tolerated by most patients on an outpatient basis. Grade 3 vomiting and leukopenia were seen in 30% and 35% of cases respectively. One patient had grade 3 esophagitis, and 1 patient was hospitalized for severe grade 4 febrile leukopenia. Although the EAP regimen cannot be considered a standard therapy for gastric cancer, the EAP schedule employed in this study seems to be better tolerated than those reported by other authors, and can sefely be given on an outpatient basis. © 1994 Springer-Verlag.
Lingua originaleEnglish
pagine (da-a)550-552
Numero di pagine3
RivistaJournal of Cancer Research and Clinical Oncology
Volume120
Stato di pubblicazionePublished - 1994

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'Etoposide, doxorubicin (Adriamycin) and cisplatin regimen in advanced gastric adenocarcinoma: experience with a lower dose schedule'. Insieme formano una fingerprint unica.

Cita questo